US-based prenatal testing technology developer Cradle Genomics yesterday picked up $17.1m in series A round co-led by Illumina Ventures, the corporate venturing subsidiary of biotechnology developer Illumina.
Section 32 co-led the round, which featured life science real estate trust Alexandria Real Estate Equities, Sea Lane Ventures, Listwin Ventures and Axon Ventures.
Cradle Genomics is developing a non-invasive prenatal test (NIPT) that analyses blood from a pregnant person to determine the genetic makeup of a foetus, helping to detect certain genetic abnormalities.
The cash injection will Cradle help launch its NIPT, while also supporting clinical development and bolstering the corporate infrastructure.
Tristan Orpin, chief executive at Cradle Genomics, said: “Our mission at Cradle Genomics is to deliver genetic knowledge for life, with a vision of better outcomes for every pregnancy.
“We are dedicated to the transformation of NIPT by offering the most comprehensive fetal genetic analysis and pregnancy health screening solutions at the earliest stages of pregnancy.”